Literature DB >> 16465663

Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.

Shu-Chen Chu1, Shun-Fa Yang, Ko-Huang Lue, Yih-Shou Hsieh, Tang-Yan Hsiao, Ko-Hsiu Lu.   

Abstract

OBJECTIVE: To determine the possible role of the plasminogen activator (PA)/plasmin system in gouty arthritis.
METHODS: We compared the antigenic values of urokinase-type PA (uPA), soluble uPA receptor (suPAR), and PA inhibitor type-1 (PAI-1) and the levels of matrix metalloproteinase-2 (MMP-2) and MMP-9 in 63 synovial fluid (SF) samples from knee joints of 38 patients with gouty arthritis and 20 SF samples from knee joints of 20 patients with osteoarthritis (OA).
RESULTS: The increases of uPA, suPAR, and PAI-1 antigenic values in SF were associated with increased levels of latent MMP-9 (pro-MMP-9) (p < 0.001, p < 0.001, p < 0.001, respectively) in gouty arthritis, whereas a correlation was not observed between uPA, suPAR, and PAI-1 antigenic values and MMP-2 levels. Increased uPA, suPAR, and PAI-1 antigenic values in gouty arthritis SF were also correlated to each other (p < 0.001, p < 0.001, p < 0.001). In gouty arthritis SF, no significant relations were observed between uPA and suPAR antigenic values and leukocyte, neutrophil, or monocyte counts, while increased values of PAI-1 corresponded closely with increased leukocyte and neutrophil counts (p = 0.005, p = 0.004). Significantly higher values of the uPA, suPAR, and PAI-1 (p < 0.001, p < 0.001, p = 0.012) appeared in SF of gouty arthritis than in SF from patients with OA.
CONCLUSION: These results show a correlation of the PA/plasmin system and MMP-9 in SF from patients with gouty arthritis, resulting in increased PA catalytic activity and contributing to inflammation in gouty arthritis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16465663

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

1.  Urokinase plasminogen activator system in synovial fibroblasts from osteoarthritis patients: modulation by inflammatory mediators and neuropeptides.

Authors:  Selene Pérez-García; Mar Carrión; Rebeca Jimeno; Ana M Ortiz; Isidoro González-Álvaro; Julián Fernández; Rosa P Gomariz; Yasmina Juarranz
Journal:  J Mol Neurosci       Date:  2013-12-07       Impact factor: 3.444

2.  Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis.

Authors:  Boris K Pliyev; Mikhail Yu Menshikov
Journal:  Inflammation       Date:  2010-02       Impact factor: 4.092

3.  A suppressive effect of prostaglandin E2 on the expression of SERPINE1/plasminogen activator inhibitor-1 in human articular chondrocytes: An in vitro pilot study.

Authors:  Kayo Masuko; Minako Murata; Naoya Suematsu; Kazuki Okamoto; Kazuo Yudoh; Hiroyuki Shimizu; Moroe Beppu; Hiroshi Nakamura; Tomohiro Kato
Journal:  Open Access Rheumatol       Date:  2009-04-17

4.  Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Level as a Predictor of the Severity of Community-Acquired Pneumonia.

Authors:  Ping-Kun Tsai; Shih-Ming Tsao; Wei-En Yang; Chao-Bin Yeh; Hsiang-Ling Wang; Shun-Fa Yang
Journal:  Int J Environ Res Public Health       Date:  2019-03-21       Impact factor: 3.390

5.  A systems pharmacology workflow with experimental validation to assess the potential of anakinra for treatment of focal and segmental glomerulosclerosis.

Authors:  Michael Boehm; Eva Nora Bukosza; Nicole Huttary; Rebecca Herzog; Christoph Aufricht; Klaus Kratochwill; Christoph A Gebeshuber
Journal:  PLoS One       Date:  2019-03-28       Impact factor: 3.240

Review 6.  The Urokinase Plasminogen Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective Therapeutic Targets.

Authors:  Benjamin J Buckley; Umar Ali; Michael J Kelso; Marie Ranson
Journal:  Curr Drug Targets       Date:  2019       Impact factor: 3.465

7.  Biological activities of phosphocitrate: a potential meniscal protective agent.

Authors:  Yubo Sun; Andrea Roberts; David R Mauerhan; Andrew R Sun; H James Norton; Edward N Hanley
Journal:  Biomed Res Int       Date:  2013-07-11       Impact factor: 3.411

8.  Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow.

Authors:  Acar Emrah; İzgi İbrahim Akın; İzci Servet; Kahyaoğlu Muzaffer; Yılmaz Mehmet Fatih; Güler Yeliz; Efe Süleyman Çağan; Güler Ahmet; Kılıçgedik Alev; Kırma Cevat
Journal:  Arch Med Sci Atheroscler Dis       Date:  2016-06-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.